As featured in The Wall Street Journal, Money Magazine, and more!

US News Annual Investing Guide, Part 2: Drugs

This article was written by in Investing. 2 comments.

drugsA few years ago, it was common for people to leave my company in the financial industry for greener pastures in the pharmaceutical industry. Salaries were higher, bonuses were up, and people were making money off their stocks. Lately, this has cooled. US News & Word Report, in the annual investing guide, agrees:

Drug patents have been expiring, allowing generic competitors to snatch away profits… Between 2005 and 2007, Pfizer has either lost or will lose patent protection on seven drugs that make up more than a quarter of its sales… After unexpected deaths, Pfizer pulled the plug last year on trials of a potential blockbuster drug to raise levels of so-called good cholesterol, while reducing the bad. Merck took arthritis drug Vioxx off the shelves late in 2004 after it was linked to increased risk of heart attacks. Safety concerns have prompted the Food and Drug Administration to limit already slow drug approvals in 2006, hampering companies’ plans to boost sales.

Now, here’s why Renuka Rayasam is recommending pharmaceutical stocks for 2007:

* It’s unlikely there will be changes in Medicare this year.
* The recent turmoil in the sector has left companies with bargain prices.
* “2007 will see the industry split, with companies that have been cutting costs and boosting pipelines perking up and those with continued problems sagging.”

Updated June 17, 2014 and originally published January 9, 2007. If you enjoyed this article, subscribe to the RSS feed or receive daily emails. Follow @ConsumerismComm on Twitter and visit our Facebook page for more updates.

Email Email Print Print
About the author

Luke Landes is the founder of Consumerism Commentary. He has been blogging and writing for the internet since 1995 and has been building online communities since 1991. Find out more about Luke Landes and follow him on Twitter. View all articles by .

{ 1 comment… read it below or add one }

avatar Nagel

I currently own PFE and it is extremely cheap. I bought it after the recent trial failure. Let’s hope it rebounds a little.

Reply to this comment

Leave a Comment

Note: Use your name or a unique handle, not the name of a website or business. No deep links or business URLs are allowed. Spam, including promotional linking to a company website, will be deleted. By submitting your comment you are agreeing to these terms and conditions.

Notify me of followup comments via e-mail. You can also subscribe without commenting.